Media Newsroom of

Epygenix Therapeutics, Inc.

140 E. Ridgewood Ave (Suite 415 South Tower)
Paramus, NJ 07652

Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company focused on discovering and developing drugs to treat rare and intractable genetic epilepsy in childhood, such as Dravet Syndrome.

Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome

Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome

​​​Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicines for Dravet Syndrome, announced today that the Company has submitted Investigational New Drug Application (IND) and Fast Track Designation Request for EPX-100 to the U.S. Food and Drug Administration…

Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of Patients With Dravet Syndrome

Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of Patients With Dravet Syndrome

Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for rare and catastrophic forms of genetic epilepsy, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation for EPX-300 for the treatment of patients…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login